Neurology · AnticonvulsantRegulatory Approvalregulatorymid-term

FDA Approval Process Update for Gabapentin ANDA214957

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/31/2026, 6:31:14 PM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's review of ANDA214957 for gabapentin signifies a critical moment in the generic market, potentially altering competitive dynamics. Portfolio teams must stay vigilant to adapt pricing and market strategies in response to the approval timeline and market entry of this generic product. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should monitor the approval timeline as it could influence market dynamics and pricing strategies for gabapentin products. The strongest clinical anchor is Hydrus® Microstent New Enrollment Post-Approval Study (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Anticonvulsant, 7 regulatory and 4 competitive items passed relevance filtering for Gabapentin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for NUPLAZID Supplement NDA210793 (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA grants priority review for NUPLAZID supplemental application. This submission indicates ongoing competition in the generic gabapentin market, which may impact pricing and availability.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Entity match (gabapentin); Regulatory pathway relevance (nda). The outcome of this FDA review will influence compliance and market access for gabapentin products, necessitating close monitoring of the approval process.

Key Risks

Elevated medium regulatory exposure for Gabapentin could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The introduction of a new generic gabapentin could lead to increased competition, affecting pricing strategies and potentially impacting revenue for existing gabapentin products.
Upside for Gabapentin may improve if Client and therapist experiences with the Processing of Positive Memories Technique (PPMT) in a randomized controlled trial: insights for protocol refinement. (PubMed) delivers favorable follow-through.
Portfolio teams should monitor the approval timeline as it could influence market dynamics and pricing strategies for gabapentin products.

What Would Change This Assessment

This becomes more urgent if Key milestones include the final approval decision and potential market entry date for the generic product.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Top-Down Attentional Control of Visual-Processing
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Buriti Suplpement on Body Composition and Function in Older Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical and Behavioral Traits of Overweight and Obese Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Urinary Vitamin C Loss in Diabetic Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ultrasound Guidance vs Landmark Technique for Internal Jugular Vein Catheterization
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for NUPLAZID Supplement NDA210793
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA grants priority review for NUPLAZID supplemental application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Fingolimod Hydrochloride Application by Alembic
Humanexa Signalsmedium relevance
Moderate corpus alignment

Client and therapist experiences with the Processing of Positive Memories Technique (PPMT) in a randomized controlled trial: insights for protocol refinement.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The dual role of exosomes in renal fibrosis and their potential for clinical translational applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Gabapentin

Commercial impact

medium

The introduction of a new generic gabapentin could lead to increased competition, affecting pricing strategies and potentially impacting revenue for existing gabapentin products.

Regulatory impact

medium

The outcome of this FDA review will influence compliance and market access for gabapentin products, necessitating close monitoring of the approval process.

What to watch

Key milestones include the final approval decision and potential market entry date for the generic product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.